<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446872</url>
  </required_header>
  <id_info>
    <org_study_id>331602</org_study_id>
    <nct_id>NCT03446872</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study for ONIVYDE® in South Korea</brief_title>
  <official_title>Post Marketing Surveillance Study for ONIVYDE® in South Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire Pharma Korea Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety of ONIVYDE when used under standard
      clinical practice in South Korea; and to describe effectiveness in patients receiving ONIVYDE
      in combination with 5-fluorouracil (5-FU) and leucovorin for the treatment of metastatic
      pancreatic cancer under standard clinical care in South Korea.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>Number of AEs by seriousness and severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3 and 4 neutropenia cases</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>Frequency of Grade 3 and 4 neutropenia cases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visit Information: Number of Visit Types</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>Number of: Outpatient/office Visits, In-hospital Visits, Phone Visits, or Other Types Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visit Information: Reason for Visits</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>Number of: Scheduled Visits, Emergency Visits, Other Types Visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Dose of ONIVYADE</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>Median Dose of ONIVYADE administered during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Dose of fluorouracil</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>Median Dose of fluorouracil administered during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Dose of Leucovorin</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>Median Dose of Leucovorin administered during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>Response duration usually is measured from the time of initial response until documented tumor progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>The time from enrollment to death from any cause, is a direct measure of clinical benefit to a patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Throughout the study period approximately 4 years</time_frame>
    <description>The time elapsed between treatment initiation and tumor progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment (EQ-5D-5 L Health Questionnaire)</measure>
    <time_frame>Baseline, and then every 3 weeks, and at the end of study visit up to approximately 4 years</time_frame>
    <description>The instrument that measures conceptual domains of quality of patients' well-being.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>All Study Participants</arm_group_label>
    <description>Patients in South Korea with a diagnosis of metastatic pancreatic cancer who have been prescribed ONIVYDE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONIVYDE</intervention_name>
    <description>irinotecan liposome injection</description>
    <arm_group_label>All Study Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>a nucleoside metabolic inhibitor</description>
    <arm_group_label>All Study Participants</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>an active metabolite of folic acid</description>
    <arm_group_label>All Study Participants</arm_group_label>
    <other_name>LV</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in South Korea with a diagnosis of metastatic pancreatic cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who are prescribed ONIVYDE per investigator's judgment shall be included if:

          -  Patient / legally authorized representative/ family member gave written informed
             consent

          -  Patient is indicated for treatment according to ONIVYDE South Korea prescribing
             information

          -  Histologically or cytologically confirmed adenocarcinoma of exocrine pancreas

          -  Documented metastatic disease

          -  Patient deemed not eligible or failed previous treatment with gemcitabine or
             gemcitabine containing therapy

          -  Adequate hepatic, renal and hematological function

        Exclusion Criteria:

          -  Patients enrolled in Shire sponsored ONIVYDE Registry or any other Shire sponsored
             ONIVYDE study

          -  Patients who have experienced severe hypersensitivity reaction to ONIVYDE or
             Irinotecan HCL

          -  Patients with new or progressive dyspnea, cough, and fever, pending diagnostic
             evaluation of interstitial lung disease. Patients with confirmed diagnosis of
             interstitial lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta now part of Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Schoengrundner, MSc</last_name>
    <phone>+43 1 20100 247 6031</phone>
    <email>petra.schoengrundner@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System - Gastroenterology</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System - Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

